Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?
LLY's leadership in GLP-1 therapies, expanding pipeline and diversified growth strategy support its long-term outlook despite a premium valuation.
Zacks
More News
Is Viking Therapeutics Stock Going to $100?
Key PointsViking Therapeutics' pipeline includes several promising weight-loss candidates...
Nasdaq News: Markets
Can Eli Lilly's New Drugs Fuel Growth Beyond Its GLP-1 Blockbusters?
LLY is expanding its revenue base beyond Mounjaro and Zepbound with new launches and label expansions that can strengthen long-term growth.
Zacks
Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?
NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk and pipeline strength.
Zacks
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views?
The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Zacks
Dyne Therapeutics vs. Viking Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Key PointsDyne Therapeutics is leveraging its FORCE platform to target rare neuromuscular diseases with high unmet need...
Nasdaq News: Markets
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $36.97, denoting a -2.38% move from the preceding trading day.
Zacks
VKTX Stock Jumps on Phase I Study Initiation for New Obesity Drug
Viking Therapeutics jumps after it starts its first human study of VK3019, expanding its obesity pipeline with a second candidate alongside its lead program, VK2735.
Zacks
VKTX Stock Eyes Best Week In 2 Years: Retail Bulls Bet Q3 Obesity Data Could Put Novo, Big Pharma In Buyout Play
Retail traders cited Novo CEO Mike Doustdar’s comment that Novo could afford a $20B, $30B or $40B deal if it was “worth it.”
Stocktwits
S&P 500, Nasdaq Close Lower On Tech Weakness But Recover After-Hours On Strong Micron Earnings — MU, AVGO, GOOGL In Focus
Broader tech sell-off continued on Wednesday as investors awaited Micron earnings to judge the demand for AI and memory chips.